Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients
Objectives:. Coronavirus disease 2019 continues to spread worldwide with high levels of morbidity and mortality. We performed anticoronavirus immunoglobulin G profiling of critically ill coronavirus disease 2019 patients to better define their underlying humoral response. Design:. Blood was collecte...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2021-03-01
|
| Series: | Critical Care Explorations |
| Online Access: | http://journals.lww.com/10.1097/CCE.0000000000000369 |
| _version_ | 1818993222758694912 |
|---|---|
| author | Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Marat Slessarev, MD, MSc Claudio M. Martin, MD, MSc Mark Daley, PhD Maitray A. Patel, BSc Michael R. Miller, PhD Eric K. Patterson, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Susanne Oehler, PhD Markus Miholits, MSc Brian Webb, PhD on behalf of the Lawson COVID-19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn |
| author_facet | Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Marat Slessarev, MD, MSc Claudio M. Martin, MD, MSc Mark Daley, PhD Maitray A. Patel, BSc Michael R. Miller, PhD Eric K. Patterson, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Susanne Oehler, PhD Markus Miholits, MSc Brian Webb, PhD on behalf of the Lawson COVID-19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn |
| author_sort | Douglas D. Fraser, MD, PhD |
| collection | DOAJ |
| description | Objectives:. Coronavirus disease 2019 continues to spread worldwide with high levels of morbidity and mortality. We performed anticoronavirus immunoglobulin G profiling of critically ill coronavirus disease 2019 patients to better define their underlying humoral response.
Design:. Blood was collected at predetermined ICU days to measure immunoglobulin G with a research multiplex assay against four severe acute respiratory syndrome coronavirus 2 proteins/subunits and against all six additionally known human coronaviruses.
Setting:. Tertiary care ICU and academic laboratory.
Subjects:. ICU patients suspected of being infected with severe acute respiratory syndrome coronavirus 2 had blood collected until either polymerase chain reaction testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative) or until death or discharge if the patient tested polymerase chain reaction positive (coronavirus disease 2019 positive).
Interventions:. None
MEASUREMENTS AND MAIN RESULTS:. Age- and sex-matched healthy controls and ICU patients who were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients had greater body mass indexes, presented with bilateral pneumonias more frequently, and suffered lower Pao2:Fio2 ratios, when compared with coronavirus disease 2019 negative patients (p < 0.05). Mortality rate for coronavirus disease 2019 positive patients was 50%. On ICU days 1–3, anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G was significantly elevated in coronavirus disease 2019 positive patients, as compared to both healthy control subjects and coronavirus disease 2019 negative patients (p < 0.001). Weak severe acute respiratory syndrome coronavirus immunoglobulin G serologic responses were also detected, but not other coronavirus subtypes. The four anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G were maximal by ICU day 3, with all four anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G providing excellent diagnostic potential (severe acute respiratory syndrome coronavirus 2 Spike 1 protein immunoglobulin G, area under the curve 1.0, p < 0.0005; severe acute respiratory syndrome coronavirus receptor binding domain immunoglobulin G, area under the curve, 0.93–1.0; p ≤ 0.0001; severe acute respiratory syndrome coronavirus 2 Spike proteins immunoglobulin G, area under the curve, 1.0; p < 0.0001; severe acute respiratory syndrome coronavirus 2 Nucleocapsid protein immunoglobulin G area under the curve, 0.90–0.95; p ≤ 0.0003). Anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G increased and/or plateaued over 10 ICU days.
Conclusions:. Critically ill coronavirus disease 2019 patients exhibited anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G, whereas serologic responses to non–severe acute respiratory syndrome coronavirus 2 antigens were weak or absent. Detection of human coronavirus immunoglobulin G against the different immunogenic structural proteins/subunits with multiplex assays may be useful for pathogen identification, patient cohorting, and guiding convalescent plasma therapy. |
| first_indexed | 2024-12-20T20:38:38Z |
| format | Article |
| id | doaj.art-b5452f32c170439fb320fdbdcd74f875 |
| institution | Directory Open Access Journal |
| issn | 2639-8028 |
| language | English |
| last_indexed | 2024-12-20T20:38:38Z |
| publishDate | 2021-03-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Critical Care Explorations |
| spelling | doaj.art-b5452f32c170439fb320fdbdcd74f8752022-12-21T19:27:09ZengWolters KluwerCritical Care Explorations2639-80282021-03-0133e036910.1097/CCE.0000000000000369202103000-00013Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 PatientsDouglas D. Fraser, MD, PhD0Gediminas Cepinskas, DVM, PhD1Marat Slessarev, MD, MSc2Claudio M. Martin, MD, MSc3Mark Daley, PhD4Maitray A. Patel, BSc5Michael R. Miller, PhD6Eric K. Patterson, PhD7David B. O’Gorman, PhD8Sean E. Gill, PhD9Susanne Oehler, PhD10Markus Miholits, MSc11Brian Webb, PhD12on behalf of the Lawson COVID-19 Study TeamRobert ArntfieldIan BallGordon BarkwellTracey BentallKaren BosmaSaoirse CameronEileen CampbellDavid CarterCarolina Gillio-MeinaRobert HegeleNatalya OdoardiRam SinghKelly SummersSue Tereschyn1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.7 Computer Science, Western University, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.11 Thermo Fisher Scientific, Vienna, Austria11 Thermo Fisher Scientific, Vienna, Austria12 Thermo Fisher Scientific, Rockford, IL.Objectives:. Coronavirus disease 2019 continues to spread worldwide with high levels of morbidity and mortality. We performed anticoronavirus immunoglobulin G profiling of critically ill coronavirus disease 2019 patients to better define their underlying humoral response. Design:. Blood was collected at predetermined ICU days to measure immunoglobulin G with a research multiplex assay against four severe acute respiratory syndrome coronavirus 2 proteins/subunits and against all six additionally known human coronaviruses. Setting:. Tertiary care ICU and academic laboratory. Subjects:. ICU patients suspected of being infected with severe acute respiratory syndrome coronavirus 2 had blood collected until either polymerase chain reaction testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative) or until death or discharge if the patient tested polymerase chain reaction positive (coronavirus disease 2019 positive). Interventions:. None MEASUREMENTS AND MAIN RESULTS:. Age- and sex-matched healthy controls and ICU patients who were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients had greater body mass indexes, presented with bilateral pneumonias more frequently, and suffered lower Pao2:Fio2 ratios, when compared with coronavirus disease 2019 negative patients (p < 0.05). Mortality rate for coronavirus disease 2019 positive patients was 50%. On ICU days 1–3, anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G was significantly elevated in coronavirus disease 2019 positive patients, as compared to both healthy control subjects and coronavirus disease 2019 negative patients (p < 0.001). Weak severe acute respiratory syndrome coronavirus immunoglobulin G serologic responses were also detected, but not other coronavirus subtypes. The four anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G were maximal by ICU day 3, with all four anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G providing excellent diagnostic potential (severe acute respiratory syndrome coronavirus 2 Spike 1 protein immunoglobulin G, area under the curve 1.0, p < 0.0005; severe acute respiratory syndrome coronavirus receptor binding domain immunoglobulin G, area under the curve, 0.93–1.0; p ≤ 0.0001; severe acute respiratory syndrome coronavirus 2 Spike proteins immunoglobulin G, area under the curve, 1.0; p < 0.0001; severe acute respiratory syndrome coronavirus 2 Nucleocapsid protein immunoglobulin G area under the curve, 0.90–0.95; p ≤ 0.0003). Anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G increased and/or plateaued over 10 ICU days. Conclusions:. Critically ill coronavirus disease 2019 patients exhibited anti–severe acute respiratory syndrome coronavirus 2 immunoglobulin G, whereas serologic responses to non–severe acute respiratory syndrome coronavirus 2 antigens were weak or absent. Detection of human coronavirus immunoglobulin G against the different immunogenic structural proteins/subunits with multiplex assays may be useful for pathogen identification, patient cohorting, and guiding convalescent plasma therapy.http://journals.lww.com/10.1097/CCE.0000000000000369 |
| spellingShingle | Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Marat Slessarev, MD, MSc Claudio M. Martin, MD, MSc Mark Daley, PhD Maitray A. Patel, BSc Michael R. Miller, PhD Eric K. Patterson, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Susanne Oehler, PhD Markus Miholits, MSc Brian Webb, PhD on behalf of the Lawson COVID-19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients Critical Care Explorations |
| title | Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients |
| title_full | Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients |
| title_fullStr | Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients |
| title_full_unstemmed | Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients |
| title_short | Detection and Profiling of Human Coronavirus Immunoglobulins in Critically Ill Coronavirus Disease 2019 Patients |
| title_sort | detection and profiling of human coronavirus immunoglobulins in critically ill coronavirus disease 2019 patients |
| url | http://journals.lww.com/10.1097/CCE.0000000000000369 |
| work_keys_str_mv | AT douglasdfrasermdphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT gediminascepinskasdvmphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT maratslessarevmdmsc detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT claudiommartinmdmsc detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT markdaleyphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT maitrayapatelbsc detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT michaelrmillerphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT erickpattersonphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT davidbogormanphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT seanegillphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT susanneoehlerphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT markusmiholitsmsc detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT brianwebbphd detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT onbehalfofthelawsoncovid19studyteam detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT robertarntfield detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT ianball detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT gordonbarkwell detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT traceybentall detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT karenbosma detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT saoirsecameron detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT eileencampbell detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT davidcarter detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT carolinagilliomeina detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT roberthegele detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT natalyaodoardi detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT ramsingh detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT kellysummers detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients AT suetereschyn detectionandprofilingofhumancoronavirusimmunoglobulinsincriticallyillcoronavirusdisease2019patients |